Medline Inc. MDLN
Composite 40/100; the shares have moved about 47% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 28/100 — a moderate mark against it.
Balance-sheet strength ranks 58/100 — a slight point in its favour.
Valuation ranks 28/100 — a moderate mark against it. Quality ranks 34/100 — a moderate mark against it. Momentum ranks 34/100 — a moderate mark against it.
What the company does Medline Inc. (MDLN) is a leading manufacturer and distributor of medical-surgical products, serving hospitals, surgery centers, physician offices, and post-acute care facilities. Its segments include Medline Brand (surgical solutions, front-line care, and lab/diagnostics) and Supply Chain Solutions.
Key financials Revenue grew 10.7% while EPS surged 1258.1%, reflecting strong top-line expansion and margin recovery. Profitability metrics are mixed: gross margin 25.9%, operating margin 5.4%, and net margin 3.3%. ROE is 6.0%, ROA 3.7%, and ROCE 4.9%, with a debt/equity of 0.65 and interest coverage of 2.27.
Stock health The stock shows weak momentum with a 3-month decline of -9.86% and 6-month drop of -11.73%. The RSI(14) is neutral at 49.50, and the stock is -23.11% below its 52-week high. Sideravia’s overall score is 43.7, with Valuation at 40.9 and Momentum at 32.2.
Price vs fair value The stock trades at a PREMIUM of 42.80% versus our fair-value estimate of 22.36 and at a discount of 29.48% versus the analyst 12-month target of 50.65. - Trading at a PREMIUM of 42.80% vs fair-value estimate (Sideravia) - Trading at a discount of 29.48% vs analyst target of 50.65 (26 analysts) - Valuation percentile 40.9/100 (Sideravia) - Forward P/E 26.25 vs trailing P/E 33.99 (Valuation data) - Weak momentum score 32.2/100 (Sideravia)
Looking forward Forward P/E of 26.25 suggests moderate earnings growth expectations, while the PEG of 0.89 implies undervaluation relative to growth. Analysts see potential upside to 50.65, but current valuation and momentum metrics temper near-term enthusiasm.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.